Christopher Yea - Aug 22, 2024 Form 4 Insider Report for KalVista Pharmaceuticals, Inc. (KALV)

Role: CHIEF DEVELOPMENT OFFICER
Signature: /s/ Benjamin L. Palleiko, Attorney-in-Fact
Stock symbol: KALV
Transactions as of: Aug 22, 2024
Transactions value $: -$23,758
Form type: 4
Date filed: 8/26/2024, 07:58 PM
Previous filing: Aug 21, 2024

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	KALV	Common Stock	Options Exercise		+3.13K	+3.7%		87.6K	Aug 22, 2024	Direct	F1
transaction	KALV	Common Stock	Sale	-$23.8K	-1.92K	-2.19%	$12.40	85.7K	Aug 23, 2024	Direct	F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	KALV	Restricted Stock Unit	Options Exercise	$0	-3.13K	-6.25%	$0.00	46.9K	Aug 22, 2024	Common Stock	3.13K		Direct	F1, F3

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Each restricted stock unit ("RSU") represents a contingent right to receive 1 share of the Issuer's Common Stock upon settlement for no consideration.
F2	The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of RSUs. The sale was to satisfy tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the Reporting Person.
F3	1/16th of the total number of shares underlying the RSUs shall vest on each quarterly anniversary of the Vesting Commencement Date thereafter, for so long as grantee's Service (as defined in the Plan) does not terminate.